1389P Two-year follow-up of KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)
| Autor: | Linch, M., Ferrario, C., Stoeckle, M., Laguerre, B., Arranz Arija, J.A., Todenhöfer, T., Fong, P.C., Piulats Rodriguez, J.M., Berry, W., Emmenegger, U., Mourey, L., Mar, N., Appleman, L.J., Joshua, A., Conter, H.J., Li, X.T., Schloss, C., Poehlein, C.H., de Bono, J.S., Yu, E.Y. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S1178-S1178 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|